These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 36618206)
21. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Ou HT; Chang KC; Li CY; Wu JS Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742 [TBL] [Abstract][Full Text] [Related]
22. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]. Ozawa H; Murai Y; Ozawa T Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054 [TBL] [Abstract][Full Text] [Related]
23. Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study. Aoki K; Nagakura M; Taguri M; Kamiyama H; Masumura M; Furuie T; Oka M; Kamiko K; Nakajima S; Akema N; Terauchi Y J Clin Med Res; 2017 Aug; 9(8):719-724. PubMed ID: 28725321 [TBL] [Abstract][Full Text] [Related]
24. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018 [TBL] [Abstract][Full Text] [Related]
25. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Benford M; Milligan G; Pike J; Anderson P; Piercy J; Fermer S Adv Ther; 2012 Jan; 29(1):26-40. PubMed ID: 22246944 [TBL] [Abstract][Full Text] [Related]
27. [One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination]. Simonyi G; Ferenci T Orv Hetil; 2016 Apr; 157(16):618-22. PubMed ID: 27063429 [TBL] [Abstract][Full Text] [Related]
28. Assessment of nonsteroidal anti-inflammatory drug use pattern using World Health Organization indicators: A cross-sectional study in a tertiary care teaching hospital of Chhattisgarh. R Vaishnavi PR; Gaikwad N; Dhaneria SP Indian J Pharmacol; 2017; 49(6):445-450. PubMed ID: 29674799 [TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of combined therapy for type 2 diabetes. Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952 [TBL] [Abstract][Full Text] [Related]
30. Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity. Lee JG; Kang DG; Yu JR; Kim Y; Kim J; Koh G; Lee D Diabetes Metab J; 2011 Apr; 35(2):149-58. PubMed ID: 21738897 [TBL] [Abstract][Full Text] [Related]
31. Pattern of Disease and Therapy for Diabetes along with Impact of Generic Prescribing on Cost of Treatment among Outpatients at a Tertiary Care Facility. Atal S; Joshi R; Balakrishnan S; Singh P; Fatima Z; Jain N J Pharm Bioallied Sci; 2021; 13(1):93-101. PubMed ID: 34084054 [TBL] [Abstract][Full Text] [Related]
32. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127 [TBL] [Abstract][Full Text] [Related]
33. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2. Huang CH; Huang YY; Hsu BR Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176 [TBL] [Abstract][Full Text] [Related]
34. Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: A national cross sectional study. Manski-Nankervis JE; Thuraisingam S; Sluggett JK; Lau P; Blackberry I; Ilomaki J; Furler J; Bell JS Prim Care Diabetes; 2019 Apr; 13(2):113-121. PubMed ID: 30262176 [TBL] [Abstract][Full Text] [Related]
35. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes. Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577 [TBL] [Abstract][Full Text] [Related]
36. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339 [TBL] [Abstract][Full Text] [Related]
37. National trends in anti-diabetic treatment in Taiwan, 2000-2009. Chang CH; Jiang YD; Chung CH; Ho LT; Chuang LM J Formos Med Assoc; 2012 Nov; 111(11):617-24. PubMed ID: 23217597 [TBL] [Abstract][Full Text] [Related]
38. Combination Therapy in Diabetes Mellitus Patients Attending Outpatient Department in a Tertiary Care Centre: A Descriptive Cross-sectional Study. Karki N; Kandel K; Shah K; Prasad P; Khanal J JNMA J Nepal Med Assoc; 2022 Dec; 60(256):1016-1020. PubMed ID: 36705114 [TBL] [Abstract][Full Text] [Related]
39. Diabetes Drug Prescription Pattern and Awareness Among Health Care Providers in Sub-Himalayan Region of India: A Population Based Study. Mokta J; Mokta K; Ranjan A; Joshi I; Garg M J Assoc Physicians India; 2017 May; 65(5):50-54. PubMed ID: 28598049 [TBL] [Abstract][Full Text] [Related]
40. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]